Issues in assessing and reducing the risk for venous thromboembolism

American Journal of Health-System Pharmacy

Volumn 67, Issue 10 SUPPL. 6, 2010, Pages

  Dager, William E ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anticoagulants; Dosage; Drugs; Heparin; Hospitals; Pharmacists, hospital; Protocols; Risk management; Team; Thrombocytopenia; Toxicity; Venous thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; DALTEPARIN; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN; TINZAPARIN; WARFARIN; ANTICOAGULANT AGENT; POLYSACCHARIDE;

CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; PHARMACIST; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; TEAMWORK; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED DISORDER; ECHOGRAPHY; REVIEW; THROMBOCYTOPENIA; UNITED STATES;

ANTICOAGULANTS; ASPIRIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; POLYSACCHARIDES; RISK ASSESSMENT; RISK FACTORS; RISK REDUCTION BEHAVIOR; THROMBOCYTOPENIA; UNITED STATES; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 77955868155     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100177     Document Type: Conference Paper

References (52)

1. Aujesky D, Guignard E, Pannatier A et al. Pharmacological thromboembolic prophylaxis in a medical ward: room for improvement. J Gen Intern Med. 2002; 17:788-91. (Pubitemid 35286244)
2. Amin A, Stemkowski S, Lin J et al. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost. 2007; 5:1610-6.
3. Arnold DM, Kahn SR, Shrier I. Missed opportunities for prevention of venous thromboembolism: an evaluation of the use of thromboprophylaxis guidelines. Chest. 2001; 120:1964-71. (Pubitemid 34053461)
4. Yu HT, Dylan ML, Lin J et al. Hospitals' compliance with prophylaxis guidelines for venous thromboembolism. Am J Health-Syst Pharm. 2007; 64:69-76. (Pubitemid 46395711)
5. Geerts WH, Bergqvist D, Pineo GF et al. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133(6 Suppl):381S-453S.
6. Lyman GH, Khorana AA, Falanga A et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007; 25:5490-505. (Pubitemid 350232226)
7. American College of Obstetricians and Gynecologists Committee on Practice Bulletins. ACOG Practice Bulletin No. 84: Prevention of deep vein thrombosis and pulmonary embolism. Obstet Gynecol. 2007; 110(2 Pt 1):429-40.
8. American Academy of Orthopaedic Surgeons. Clinical guideline on pulmonary embolism in patients undergoing total hip or knee arthroplasty. May 2007. www.aaos.org/Research/guidelines/PE-guideline.pdf (accessed 2009 Dec 11).
9. Ozbudak O, Erogullari I, Ogus C et al. Doppler ultrasonography versus venography in the detection of deep vein thrombosis in patients with pulmonary embolism. J Thromb Thrombolysis. 2006; 21:159-62.
10. Oster G, Ollendorf DA, Vera-Llonch M et al. Economic consequences of venous thromboembolism following major orthopedic surgery. Ann Pharmacother. 2004; 38:377-82. (Pubitemid 38235324)
11. Caprini JA. Thrombosis risk assessment as a guide to quality patient care. Dis Mon. 2005; 51:70-8.
12. Lutz L, Haas S, Hach-Wunderle V et al. Venous thromboembolism in internal medicine: risk assessment and pharmaceutical prophylaxis: publication for the specialist platform. Med Welt. 2002; 53:231-4. (Pubitemid 34982622)
13. Khorana AA, Kuderer NM, Culakova E et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood. 2008; 111:4902-7.
14. Francis CW. Clinical practice. Prophylaxis for thromboembolism in hospitalized medical patients. N Engl J Med. 2007; 356:1438-44. (Pubitemid 46562358)
15. Miller A, Roche LM. Surgical Care Improvement Project: from SIP to SCIP.November/December 2007. www.medicarepatientmanagement.com/issues/02-06/ mpmND07-SurgicalMiller.pdf (accessed 2009 Dec 12).
16. White RH, Romano PS, Zhou H et al. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med. 1998; 158:1525-31. (Pubitemid 28340985)
17. Borris LC. Rivaroxaban and dabigatran etexilate: two new oral anticoagulants for extended postoperative prevention of venous thromboembolism after elective total hip arthroplasty. Arch Orthop Trauma Surg. 2009; June 30 [epub ahead of print].
18. Turpie AG, Bauer KA, Eriksson BI et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med. 2002; 162:1833-40.
19. Prandoni P, Villalta S, Bagatella P et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997; 82:423-8.
20. Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133(6 Suppl):454S-545S.
21. Fuster V, Rydén LE, Cannom DS et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006; 114:e257-354.
22. Robinson KS, Anderson DR, Gross M et al. Ultrasonographic screening before hospital discharge for deep venous thrombosis after arthroplasty: the postarthroplasty screening study. A randomized, controlled trial. Ann Intern Med. 1997; 127:439-45.
23. Dager W, King J, Meehan J et al. Clinical outcomes using subcutaneous unfractionated heparin and warfarin after elective total hip or total knee arthroplasty. Presented at the American College of Clinical Pharmacy 2006 Spring Practice and Research Forum. Monterey, CA: April 9-12, 2006. Abstract 48. www.pharmacotherapy.org/pdf/ACCP-Spring-Abstracts-2006.pdf (accessed 2009 Dec 13).
24. Powers PJ, Gent M, Jay RM et al. A randomized trial of less intense postoperative warfarin or aspirin therapy in the prevention of venous thromboembolism after surgery for fractured hip. Arch Intern Med. 1989; 149:771-4.
25. Rose AJ, Ozonoff A, Berlowitz DR et al. Warfarin dose management affects INR control. J Thromb Haemost. 2009; 7:94-101.
26. Neel S. Essential warfarin knowledge. In: Managing anticoagulation patients in the hospital. Bethesda, MD: American Society of Health-System Pharmacists; 2007:133-75.
27. Guyatt GH, Cook DJ, Jaeschke R et al. Grades of recommendation for antithrombotic agents: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133(6 Suppl):123S-31S.
28. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000; 355:1295-302.
29. Nutescu EA, Spinler SA, Wittkowsky A et al. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009; 43:1064-83.
30. Siguret V, Pautas E, Fevrier M et al. El derly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days. Thromb Haemost. 2000; 84:800-4.
31. Cestac P, Bagheri H, Lapeyre-Mestre M et al. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Saf. 2003; 26:197-207.
32. Samama MM, Verhille C, Carchy L. Relation between weight, obesity, and frequency of deep venous thrombosis after enoxaparin in orthopedic surgery. Thromb Haemost. 1995; 73:977. Abstract 300.
33. Scholten DJ, Hoedema RM, Scholten SE. A comparison of two different prophylactic dose regimens of low molecular weight heparin in bariatric surgery. Obes Surg. 2002; 12:19-24
34. Raftopoulos I, Martindale C, Cronin A et al. The effect of extended post-discharge chemical prophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial. Surg Endosc. 2008; 22:2834-91.
35. Kucher N, Leizorovicz A, Vaitkus PT et al. Efficacy and safety of fixed low-dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients: a subgroup analysis of the prevent trial. Arch Intern Med. 2005;165:341-5. (Pubitemid 40216291)
36. Hacquard M, Mainard D, de Maistre E et al. Influence on injection site of prophylactic dose enoxaparin bioavailability in obese patients. J Thromb Haemost. 2007; 5(Suppl 2):P-M-669.
37. Haas CE, Nelsen JL, Raghavendran K et al. Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma. 2005; 59:1336-43.
38. Mayr AJ, Dünser M, Jochberger S et al. Antifactor Xa activity in intensive care patients receiving thromboembolic prophylaxis with standard doses of enoxaparin. Thromb Res. 2002; 105:201-4.
39. Priglinger U, Delle Karth G, Geppert A et al. Prophylactic anticoagulation with enoxaparin: is the subcutaneous route appropriate in the critically ill? Crit Care Med. 2003; 31:1405-9.
40. Simoons ML, Bobbink IW, Boland J et al. A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the Pentasaccharide in Unstable Angina (PENTUA) Study. J Am Coll Cardiol. 2004; 43:2183-90.
41. The Rembrandt Investigators. Treatment of proximal deep vein thrombosis with a novel synthetic compound (SR90107A/ORG31540) with pure anti-factor Xa activity: a phase II evaluation. Circulation. 2000; 102:2726-31.
42. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators, Yusuf S, Mehta SR, Chrolavicius S et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006; 354:1464-76.
43. Davidson BL, Buller HR, Decousus H et al. Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials. J Thromb Haemost. 2007; 5:1191-4. (Pubitemid 46902121)
44. U.S. Food and Drug Administration. Arixtra (fondaparinux sodium) injection. August 2009. www.fda.gov/Safety/MedWatch/SafetyInformation/ucm182229. htm (accessed 2009 Dec 14).
45. Arixtra package insert. Research Triangle Park, NC: GlaxoSmithKline; 2009 Oct.
46. Nutescu E, Dager W. Heparin, low molecular weight heparin, and fondaparinux. In: Managing anticoagulation patients in the hospital. Bethesda, MD: American Society of Health-System Pharmacists; 2007:177-202.
47. Warkentin TE, Greinacher A, Koster A et al. Treatment and prevention of heparin-induced thrombocytopenia. American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008; 133(6 Suppl):340S-80S.
48. Grouze E, Kryriakou E, Panagou I et al. Fondaparinux for the treatment of acute heparin induced thrombocytopenia: a single-center experience. Clin Appl Thromb Hemost. 2009; Oct 13 [epub ahead of print].
49. Walenga JM, Prechel M, Jeske WP et al. Rivaroxaban - an oral, direct Factor Xa inhibitor - has potential for the management of patients with heparin-induced thrombocytopenia. Br J Haematol. 2008; 143:92-9.
50. Matthai WH Jr. Treatment of heparin-induced thrombocytopenia in cardiovascular patients. Expert Opin Pharmacother. 2006; 7:267-76.
51. Dager WE, Lee A, Gosselin RC et al. Exploring adult patient populations at risk for developing HIT. J Thromb Haemost. 2007; 5(S2) P-T-329.
52. Schmidt B, Michler R, Klein M et al. Ultrasound screening for distal vein thrombosis is not beneficial after major orthopedic surgery. A randomized controlled trial. Thromb Haemost. 2003; 90:949-54.